June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Ocular Complications in HZO and Rates of Herpes Zoster Vaccination
Author Affiliations & Notes
  • Amy Song
    Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
    Department of Ophthalmology & Visual Sciences, University of Illinois Chicago College of Medicine, Chicago, Illinois, United States
  • Arya Kadakia
    Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
    Department of Ophthalmology & Visual Sciences, University of Illinois Chicago College of Medicine, Chicago, Illinois, United States
  • Ann-Marie Lobo
    Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
    Department of Ophthalmology & Visual Sciences, University of Illinois Chicago College of Medicine, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Amy Song None; Arya Kadakia None; Ann-Marie Lobo None
  • Footnotes
    Support  P30 EY001792; NIH/NEI K12 EY021475; UIC CCTS 2019-01; Unrestricted departmental funding from Research to Prevent Blindness; UIC CCTS, NCATS, UL1TR002003
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4834. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amy Song, Arya Kadakia, Ann-Marie Lobo; Ocular Complications in HZO and Rates of Herpes Zoster Vaccination. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4834.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the epidemiology of herpes zoster ophthalmicus (HZO) and herpes zoster vaccination in an urban hospital system and to examine rates of ocular complications in HZO.

Methods : A retrospective chart review of patients with herpes zoster (HZ), HZO with ocular involvement based on ICD-9 and ICD-10 codes, and any shingles vaccination based on CPT codes at University of Illinois Hospital systems from 2010-2021 was performed. For patients with HZO, demographic information, medications, exam findings, and ocular complications at 6 months and 1 year after initial encounter were recorded.

Results : During the study period, 1872 patients out of 1,009,419 patients over age 18 had HZ (0.19%) and 209 patients had HZO (11.2%).

Of 119 patients diagnosed with HZO with ocular involvement, mean age was 58.7 years, 56.7% were female, and 30.8% were Caucasian. 93.3% received antivirals and 25% were immunocompromised. There was a mean of 5.2 days between symptom onset and treatment initiation.

Ocular involvement included 60 cases of conjunctivitis (50.4%), 51 epithelial keratitis (42.9%), 44 stromal keratitis (37%), 21 endothelial keratitis (17.6%), 40 uveitis (33.6%). In total, 43 patients developed ocular complications within 1 year; 33 and 36 patients at 6 months and 1 year, respectively. Ocular complications included: corneal scarring or neovascularization (42.4%), keratitis (23.5%), reduced corneal sensation (20.5%), glaucoma (7.6%), and uveitis (6.1%).

Of patients who developed complications, 70% were female and 44% were Caucasian. 97.6% were prescribed antivirals, 40% were prescribed steroids, and 35.1% were immunocompromised. Initial ocular presentation included 13 conjunctivitis (32.5%), 17 epithelial keratitis (40.5%), 24 stromal keratitis (57.1%), 10 endothelial keratitis (25%), 16 uveitis (39%). Stromal keratitis (OR 4.7; 95% CI 1.66, 13.42) and female gender (OR 3.7; 95% CI 1.29, 10.82) were significantly associated with a higher risk for ocular complications in HZO.

Of 350,196 adults over 50 years eligible for vaccination, 3280 (0.94%) received Shingrix and 2568 (0.73%) received Zostavax. Of patients who received any shingles vaccination, mean age was 62.6 years, 60% were female, and 48.8% were Black.

Conclusions : In an urban hospital system and tertiary care ophthalmology clinic, over 35% of patients with HZO developed ocular complications. Rates of shingles vaccination were very low at less than 1% of the eligible population.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×